Allogene Therapeutics (ALLO) Announces Proposed $450M Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Allogene Therapeutics (ALLO) Prices 11.7M Share Common Offering at $47/Sh
June 2, 2020 5:50 AM EDTAllogene Therapeutics, Inc. (NASDAQ: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of $47.00 per share. The gross proceeds from this offering are expected to be approximately $550.0 million, before deducting underwriting... More
Allogene (ALLO) PT Raised to $44 at Stifel
June 1, 2020 4:56 AM EDTStifel analyst Benjamin Burnett raised the price target on Allogene (NASDAQ: ALLO) to $44.00 (from $27.00) while maintaining a Hold rating.... More
UPDATE: Raymond James Downgrades Allogene (ALLO) to Market Perform
May 31, 2020 10:01 PM EDT(Updated - June 1, 2020 6:36 AM EDT)
(updating comment)
Raymond James analyst Dane Leone downgraded Allogene (NASDAQ: ALLO) from Outperform to Market Perform.
The analyst comments "We are downgrading our recommendation of ALLO to Market Perform from Outperform as the ASCO 2020 dataset for ALLO-501 has... More
Allogene (ALLO) PT Raised to $53 at JMP Securities
May 31, 2020 5:46 PM EDTJMP Securities analyst Reni Benjamin raised the price target on Allogene (NASDAQ: ALLO) to $53.00 (from $37.00) while maintaining a Market Outperform rating.
The analyst comments "The company presented the first efficacy and safety data from the ongoing Phase 1 trial of the CD19-targeting allogeneic... More
Allogene (ALLO) PT Raised to $66 at Goldman Sachs
May 29, 2020 1:53 PM EDTGoldman Sachs analyst Salveen Richter raised the price target on Allogene (NASDAQ: ALLO) to $66.00 (from $45.00) while maintaining a Buy rating.
... MoreAllogene (ALLO) PT Raised to $55 at H.C. Wainwright
May 29, 2020 12:12 PM EDTH.C. Wainwright analyst Debjit Chattopadhyay raised the price target on Allogene (NASDAQ: ALLO) to $55.00 (from $42.00) while maintaining a Buy rating.
... MoreAllogene (ALLO) PT Raised to $70 at Piper Sandler
May 29, 2020 10:56 AM EDTPiper Sandler analyst Tyler Van Buren raised the price target on Allogene (NASDAQ: ALLO) to $70.00 (from $50.00) while maintaining a Overweight rating.
... MoreAllogene Therapeutics (ALLO) with Collaborator Servier Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at ASCO
May 29, 2020 8:12 AM EDTAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, in collaboration with development partner Servier, an independent international pharmaceutical company, today announced positive initial results from Allogenes dose escalation Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma (NHL). Data were presented at the American Society of Clinical Oncology (ASCO) annual meeting. This study utilizes ALLO-647, Allogene's anti-CD52 monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen.
We are very pleased with these initial Phase 1... More
